本文選題：潰瘍性結(jié)腸炎 + 泄瀉　； 參考：《河北醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:觀察化濁解毒愈腸方聯(lián)合美沙拉嗪治療潰瘍性結(jié)腸炎的臨床療效方法:將符合納入標(biāo)準(zhǔn)的60例潰瘍性結(jié)腸炎患者,按隨機(jī)數(shù)字表法分為治療組和對(duì)照組,各組30例。兩組患者在性別、年齡、病程、病情嚴(yán)重程度、癥狀、體征等方面均無(wú)統(tǒng)計(jì)學(xué)差異。治療組予以化濁解毒愈腸方口服聯(lián)合美沙拉嗪腸溶片口服治療,對(duì)照組予以美沙拉嗪腸溶片口服治療,2周1個(gè)療程,連續(xù)服用為2個(gè)療程,治療結(jié)束6個(gè)月后隨訪,觀察兩組治療前后的總療效、主要癥狀體征、結(jié)腸鏡下黏膜的變化及不良反應(yīng)和復(fù)發(fā)的情況。結(jié)果:1兩組總體療效比較,治療組總有效率90%。對(duì)照組總有效率83.3%;兩組比較經(jīng)秩和檢驗(yàn),P0.05,具有統(tǒng)計(jì)學(xué)意義,表明治療組綜合療效優(yōu)于對(duì)照組。2兩組腹瀉、黏液膿血便、腹痛、里急后重等主要癥狀療效比較治療組與對(duì)照組組內(nèi)治療前與治療后比較,采用秩和檢驗(yàn),P0.05,均有統(tǒng)計(jì)學(xué)意義,表明兩組治療均有效。治療后,治療組與對(duì)照組組間比較,經(jīng)秩和檢驗(yàn),P0.05,具有統(tǒng)計(jì)學(xué)意義,治療組療效優(yōu)于對(duì)照組。3治療后兩組腸鏡下黏膜病變改善的比較治療組和對(duì)照組組內(nèi)比較,治療組在治療前后比較,采用秩和檢驗(yàn),P0.05,有統(tǒng)計(jì)學(xué)意義,治療組治療有效,對(duì)照組在治療前后比較,采用秩和檢驗(yàn),P0.05,無(wú)統(tǒng)計(jì)學(xué)意義。治療后,治療組與對(duì)照組組間比較,經(jīng)秩和檢驗(yàn),P0.05,具有統(tǒng)計(jì)學(xué)意義,治療組在改善鏡下黏膜病變方面優(yōu)于對(duì)照組。4不良反應(yīng)及復(fù)發(fā)情況比較,兩組治療期間均無(wú)不良反應(yīng)發(fā)生,治療結(jié)束6個(gè)月隨訪,治療組復(fù)發(fā)1例,對(duì)照組復(fù)發(fā)6例。結(jié)論:通過(guò)本項(xiàng)臨床觀察,治療組和對(duì)照組對(duì)潰瘍性結(jié)腸炎均有治療效果,從腹瀉、黏液膿血、腹痛等癥狀體征來(lái)評(píng)價(jià),中藥化濁解毒愈腸方加減口服治療潰瘍性結(jié)腸炎有明顯的療效,且中藥化濁解毒愈腸方加減口服加美沙拉嗪口服治療潰瘍性結(jié)腸炎的臨床療效明顯優(yōu)于單用美沙拉嗪,且可有效防止?jié)冃越Y(jié)腸炎的復(fù)發(fā),在臨床治療中是切實(shí)可行的方法。
[Abstract]:Objective: to observe the clinical efficacy of Huazhuojiedu Yuchang recipe (Huazhujiedu Yuchang decoction) combined with mesalazine in the treatment of ulcerative colitis. Methods: 60 patients with ulcerative colitis were divided into treatment group (n = 30) and control group (n = 30). There were no significant differences in sex, age, course, severity, symptoms and signs between the two groups. The treatment group was treated with Huazhuojiedu Yuchang decoction and mesalazine enteric-coated tablets orally, while the control group was treated with mesalazine enteric-coated tablets for 2 weeks and 2 consecutive courses of treatment, followed up for 6 months after the end of the treatment. The total curative effect, main symptoms and signs, mucosal changes under colonoscopy, adverse reactions and recurrence were observed before and after treatment. Results compared with the two groups, the total effective rate of the treatment group was 90%. The total effective rate of the control group was 83.3%, the comparison of the two groups by rank sum test (P0.05) had statistical significance, which indicated that the comprehensive curative effect of the treatment group was better than that of the control group (group .2) with diarrhea, mucus, blood stool and abdominal pain. Comparison of curative effect between the treatment group and the control group before and after treatment, the rank sum test was used to test P0.05, all of which had statistical significance, indicating that the treatment was effective in both groups. After treatment, the comparison between the treatment group and the control group showed that the rank sum test showed that the curative effect of the treatment group was better than that of the control group (P 0.05), and the curative effect of the treatment group was better than that of the control group (P < 0.05), and the comparison between the treatment group and the control group was better than that in the control group. Compared before and after treatment, the treatment group was treated with rank sum test (P 0.05), the treatment group was effective, and the control group was compared before and after treatment with rank sum test (P 0.05), which had no statistical significance. After treatment, compared with the control group, the rank sum test (P 0.05) was statistically significant. The treatment group was superior to the control group in improving the pathological changes of mucosa under microscope. At the end of 6 months follow-up, 1 case in the treatment group and 6 cases in the control group. Conclusion: both the treatment group and the control group have therapeutic effects on ulcerative colitis through the clinical observation. The symptoms and signs of diarrhea, mucus abscess, abdominal pain and so on are evaluated. The Chinese medicine Huazhuo jiedu Yuchang decoction plus and subtractive oral treatment of ulcerative colitis has obvious curative effect, and the clinical curative effect of traditional Chinese medicine Huazhuo jiedu Yuchang prescription plus subtractive oral mesalazine oral in the treatment of ulcerative colitis is obviously better than that of single mesalazine alone in the treatment of ulcerative colitis. It can effectively prevent the recurrence of ulcerative colitis and is a feasible method in clinical treatment.
【學(xué)位授予單位】：河北醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R574.62

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 欒炳玉;;針灸治療潰瘍性結(jié)腸炎療效觀察[J];亞太傳統(tǒng)醫(yī)藥;2016年20期

2 劉明坤;于博文;陶夏平;;陶夏平辨治潰瘍性結(jié)腸炎經(jīng)驗(yàn)淺析[J];中華中醫(yī)藥雜志;2016年10期

3 鐘偉;;美沙拉嗪聯(lián)合加味甘草瀉心湯治療潰瘍性結(jié)腸炎臨床觀察[J];中國(guó)民族民間醫(yī)藥;2016年18期

4 王璋;吳泉峰;;血清自身抗體P-ANCA及GAB檢測(cè)在潰瘍性結(jié)腸炎中的臨床診斷價(jià)值探討[J];檢驗(yàn)醫(yī)學(xué)與臨床;2016年16期

5 馬勇;;白頭翁湯加味保留灌腸治療潰瘍性結(jié)腸炎60例臨床觀察[J];世界最新醫(yī)學(xué)信息文摘;2016年28期

6 王勝文;;中醫(yī)綜合療法治療潰瘍性結(jié)腸炎42例[J];河南中醫(yī);2016年04期

7 龍慶;李俊;聞?dòng)?;疏肝健脾法聯(lián)合保留灌腸治療肝郁脾虛型潰瘍性直腸炎臨床研究[J];河南中醫(yī);2016年03期

8 宋博;;潰瘍性結(jié)腸炎的中醫(yī)辯證治療[J];中國(guó)衛(wèi)生標(biāo)準(zhǔn)管理;2015年31期

9 陳建輝;;中西醫(yī)結(jié)合治療潰瘍性結(jié)腸炎的臨床療效觀察[J];現(xiàn)代醫(yī)藥衛(wèi)生;2015年03期

10 丁莉;田先翔;吳勇;陳靚;;板橋黨參對(duì)腸黏膜損傷修復(fù)的作用[J];西部中醫(yī)藥;2014年11期

相關(guān)會(huì)議論文 前1條

1 杜艷茹;張紈;李佃貴;;從濁毒論治潰瘍性結(jié)腸炎[A];中華中醫(yī)藥學(xué)會(huì)脾胃病分會(huì)第二十次全國(guó)脾胃病學(xué)術(shù)交流會(huì)論文匯編[C];2008年

相關(guān)碩士學(xué)位論文 前1條

1 鄧燕莉;厚樸酚與和厚樸酚抗腹瀉作用及分子機(jī)理研究[D];湖南農(nóng)業(yè)大學(xué);2012年

，

本文編號(hào)：1832626